ASCO 2022 Highlights Podcast Presented ByDr Robert van den Heuvel, Medicom ConferenceASCO 2022 21 June, 2022 09:38
Modest activity of atezolizumab plus bevacizumab in Child-Pugh B HCC Presented ByDr Hyeyeong Kim, Ulsan University Hospital, South Korea TrialPhase 3, IMbrave150 ConferenceASCO GI 2022 21 March, 2022 10:00
Immune chemo-sensitisation looks promising in microsatellite-stable mCRC Presented ByDr Filippo Pietrantonio, Istituto Nazionale dei Tumori di Milano, Italy & Dr Chiara Cremolini, Azienda Ospedaliero-Universitaria Pisana, Italy TrialPhase 2, MAYA & AtezoTRIBE ConferenceESMO 2021 19 November, 2021 09:42
Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer Presented ByProf. Nicoletta Colombo, Istituto Europeo di Oncologia, Italy TrialPhase 3, KEYNOTE-826 ConferenceESMO 2021 19 November, 2021 09:23
Real-world data shows inferior survival compared with IMpower150 results Presented ByDr Samantha Dean, Austin Health, Australia TrialPhase 3, IMpower150 ConferenceWCLC 2021 21 September, 2021 13:23
Novel drug combination for recurrent ovarian cancer Presented ByProf. David O’Malley, Ohio State University, OH, USA TrialPhase 1/2, FORWARD II ConferenceASCO 2021 12 August, 2021 22:43
Landmark OS for HCC, updated IMbrave150 data Presented ByProf. Richard Finn, UCLA, USA TrialPhase 3, IMbrave150 ConferenceASCO GI 2021 12 March, 2021 11:39
Predicting resistance to first-line FOLFOX plus bevacizumab in mCRC using circulating markers Presented ByProf. Thomas Seufferlein, University of Ulm, Germany TrialPhase 1/2, PERMAD ConferenceASCO GI 2021 12 March, 2021 11:37
Final OS analyses comparing trifluridine/tipiracil + bevacizumab versus capecitabine + bevacizumab in first-line unresectable mCRC patients noneligible for intensive therapy Presented ByProf. Eric Van Cutsem, KU Leuven, Belgium TrialPhase 2, TASCO1 ConferenceASCO GI 2021 12 March, 2021 11:35
Atezolizumab/bevacizumab for non-squamous NSCLC with high PD-L1 expression ConferenceESMO 2020 25 November, 2020 14:58
Understanding MIBC biology for novel treatment options Presented ByProf. Yohann Loriot, Université Paris-Saclay, France TrialBLC2001; THOR; EV-301; EV-302; TROPHY-U-01; RANGE ConferenceEAU 2020 20 August, 2020 12:36
Ovarian cancer patients benefit from combined maintenance therapy Presented ByProf. Isabelle Ray-Coquard, Université Claude Bernard, Lyon, France TrialPhase 3, PAOLA-1/ENGOT-ov25 ConferenceESMO 2019 26 November, 2019 23:25
Adding bevacizumab to temozolomide-based therapy in neuroblastoma TrialPhase 2, BEACON-Neuroblastoma ConferenceESMO 2019 26 November, 2019 14:29
FOLFOXIRI plus bevacizumab an option for patients with mCRC and poor prognosis Presented ByDr Javier Sastre, Hospital Clínico San Carlos, Spain TrialPhase 3, VISNU-1 ConferenceASCO 2019 15 July, 2019 23:53
Other I-O combinations Presented ByProf. Solange Peters, Lausanne University Hospital and Ludwig Institute, Switzerland TrialIMpower 150 ConferenceELCC 2019 25 June, 2019 21:17
Combination therapies: Where are we in 2018? Presented ByProf. Martin Reck, German Center for Lung Research, Germany ConferenceWCLC 2018 21 November, 2018 22:05
